Risk factors and drugs in the treatment of hypertension

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Clinical Trials

Background:

• Hypertension therapy has improved outcomes but requires further advancements, particularly for coronary artery disease.
• Centrally acting agents are commonly used in hypertension clinical trials, showing significant benefits.

Purpose of the Study:

• To identify future drug targets for hypertension management with improved safety profiles.
• To evaluate the potential of centrally acting imidazoline agonists in addressing unmet needs in hypertension treatment.

Main Methods:

• Review of existing hypertension clinical trial data.
• Analysis of drug side effect profiles, including metabolic and central nervous system effects.
• Assessment of drug-induced electrolyte imbalances and rebound hypertension phenomena.

Main Results:

• Current hypertension therapies, while beneficial, have limitations regarding specific complications.
• Need for antihypertensive agents that do not exacerbate diabetes mellitus, dyslipidemia, or cause hypokalemia.
• Drowsiness, depression, and rebound hypertension are undesirable side effects to avoid.

Conclusions:

• Future hypertension drug development should prioritize agents with favorable metabolic and side effect profiles.
• Centrally acting imidazoline agonists represent a promising class for further investigation in hypertension.
• Minimizing adverse effects and avoiding rebound hypertension are critical for long-term patient well-being.